title: Extramedullary plasmacytomas and solitary plasma cell tumours of bone.
abstract: We describe clinical features and treatment results in 25 patients with solitary osseous (SOP) and 18 patients with solitary extramedullary plasmacytoma (EMP). 41 patients were treated with high-voltage radiotherapy, median 40 Gy in 20 fractions. Surgery was part of the treatment in 21 and chemotherapy in 5 patients. The median age in both groups was 56 years, with a preponderance of males. Myelomatosis developed in 10 SOP and 2 EMP patients, and this development did not correlate with the presence or absence of an M-component at the time of diagnosis of plasmacytoma. The estimated 5- and 10-y survival was 87% and 76% without a statistical difference between SOP and EMP groups. The patients in the SOP group usually died from myelomatosis while EMP patients died from other causes.
authors.affiliation: Department of Oncology, Norwegian Radium Hospital, Oslo.
authors.forename: L
authors.initials: L
authors.lastname: Brinch
authors.forename: E
authors.initials: E
authors.lastname: Hannisdal
authors.forename: A F
authors.initials: AF
authors.lastname: Abrahamsen
authors.forename: S
authors.initials: S
authors.lastname: Kvaløy
authors.forename: R
authors.initials: R
authors.lastname: Langholm
mesh_terms: D001536:Bence Jones Protein / Q000032:analysis; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010954:Plasmacytoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D001536:Bence Jones Protein